Ameriprise
NTLA icon

Ameriprise’s Intellia Therapeutics NTLA Stock Holding History

Ameriprise’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Buy
128,209
+54,683
+74% +$697K ﹤0.01% 3045
2025
Q4 		$661K Buy
73,526
+23,879
+48% +$329K ﹤0.01% 3520
2025
Q3 		$857K Buy
49,647
+37,844
+321% +$466K ﹤0.01% 3433
2025
Q2 		$111K Buy
11,803
+1,443
+14% +$11.8K ﹤0.01% 3875
2025
Q1 		$73.7K Sell
10,360
-21,349
-67% -$216K ﹤0.01% 3913
2024
Q4 		$370K Buy
31,709
+529
+2% +$8.26K ﹤0.01% 3642
2024
Q3 		$641K Sell
31,180
-4,791
-13% -$110K ﹤0.01% 3399
2024
Q2 		$804K Buy
35,971
+3,851
+12% +$91.7K ﹤0.01% 3242
2024
Q1 		$884K Sell
32,120
-277,092
-90% -$7.7M ﹤0.01% 3218
2023
Q4 		$9.43M Buy
309,212
+275,857
+827% +$7.93M ﹤0.01% 1831
2023
Q3 		$1.05M Buy
33,355
+16,602
+99% +$644K ﹤0.01% 3119
2023
Q2 		$683K Buy
16,753
+266
+2% +$10.8K ﹤0.01% 3321
2023
Q1 		$614K Sell
16,487
-394,335
-96% -$15.5M ﹤0.01% 3345
2022
Q4 		$14.3M Sell
410,822
-24,154
-6% -$1.15M ﹤0.01% 1446
2022
Q3 		$24.3M Buy
434,976
+20,819
+5% +$1.29M 0.01% 1062
2022
Q2 		$21.4M Sell
414,157
-18,003
-4% -$914K 0.01% 1168
2022
Q1 		$31.4M Sell
432,160
-5,330
-1% -$452K 0.01% 1032
2021
Q4 		$51.7M Buy
437,490
+713
+0.2% +$89.3K 0.01% 828
2021
Q3 		$58.6M Buy
436,777
+219,321
+101% +$33.2M 0.02% 694
2021
Q2 		$35.2M Buy
217,456
+202,813
+1,385% +$15.8M 0.01% 967
2021
Q1 		$1.22M Buy
14,643
+6,490
+80% +$436K ﹤0.01% 3064
2020
Q4 		$312K Buy
+8,153
New +$296K ﹤0.01% 3494
2019
Q4 		– Sell
-11,281
Closed -$150K – 3745
2019
Q3 		$150K Sell
11,281
-23,570
-68% -$376K ﹤0.01% 3601
2019
Q2 		$570K Buy
34,851
+23,057
+195% +$362K ﹤0.01% 3284
2019
Q1 		$202K Buy
+11,794
New +$176K ﹤0.01% 3554
2018
Q4 		– Sell
-94,381
Closed -$2.7M – 3733
2018
Q3 		$2.7M Sell
94,381
-9,640
-9% -$280K ﹤0.01% 2690
2018
Q2 		$2.76M Buy
+104,021
New +$2.52M ﹤0.01% 2589

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise's NTLA Position: Q1 2026 in Review

Ameriprise increased its Intellia Therapeutics (NTLA) stake by 74% in Q1 2026, buying an estimated $697K and bringing the position to 128,209 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Ameriprise first reported a position in NTLA in Q2 2018 and has held it in 27 quarters since. The position peaked at $58.6M in Q3 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Ameriprise held 128,209 shares of Intellia Therapeutics worth $1.64M as of Q1 2026.
  • Ameriprise bought 54,683 Intellia Therapeutics shares in Q1 2026, an estimated $697K.
  • Intellia Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3045 holding.
  • Ameriprise first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 27 quarters since.
  • Ameriprise's Intellia Therapeutics position peaked at $58.6M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.